Philipson, Tomas J.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Tomas J. Philipson American economist
VIAF ID: 7474434 (Personal)
Permalink: http://viaf.org/viaf/7474434
Preferred Forms
-
200 _ |
‡a
Philipson
‡b
Tomas J.
-
100 1 _
‡a
Philipson, Tomas J
-
100 1 _ ‡a Philipson, Tomas J
-
100 1 _
‡a
Philipson, Tomas J.
-
100 1 _ ‡a Philipson, Tomas J.
-
100 1 _
‡a
Philipson, Tomas J.
-
100 1 _ ‡a Philipson, Tomas J.
-
100 1 _
‡a
Philipson, Tomas J.
-
100 1 _
‡a
Philipson, Tomas J.
-
100 1 _ ‡a Philipson, Tomas J.
-
100 0 _
‡a
Tomas J. Philipson
‡c
American economist
4xx's: Alternate Name Forms (17)
5xx's: Related Names (13)
- 510 2 _
‡a
American Enterprise Institute
- 510 2 _
‡a
Irving B. Harris Graduate School of Public Policy Studies (Chicago, Ill.)
- 510 2 _
‡a
Irving B. Harris Graduate School of Public Policy Studies
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
Manhattan Institute
- 510 2 _
‡a
National Bureau of Economic Research
- 510 2 _
‡a
National Bureau of Economic Research (Cambridge, Mass.)
- 510 2 _
‡a
National Bureau of Economic Research (NBER)
- 510 2 _
‡a
National Bureau of Economic Research
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
Rand Corporation
- 510 2 _
‡a
Rand Corporation
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 510 2 _
‡a
University (Chicago, Ill.)
‡b
Department of Economics
- 510 2 _
‡a
University of Chicago / Harris School of Public Policy
- 510 2 _
‡a
University of Chicago
‡b
Department of Economics
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
Works
| Title | Sources |
|---|---|
| Adjusting National Accounting for Health: Is the Business Cycle Countercyclical? |
|
| Aging and the growth of long-term care, c1999: |
|
| Antitrust in the Not-For-Profit Sector |
|
| Assessing the safety and efficacy of the FDA : the case of the prescription drug user fee acts |
|
| Can medical progress be sustained? implications of the link between development and output markets |
|
| Consumption vs. Production of Insurance |
|
| Data markets and optimal sample size determination |
|
| Disease Complementarities and the Evaluation of Public Health Interventions |
|
| The dual effects of intellectual property regulations : within- and between- patent competition in the US pharmaceuticals industry |
|
| Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension |
|
| Economic Epidemiology and Infectious Diseases |
|
| An Economic Evaluation of the War on Cancer |
|
| The Effects of Product Liability Exemption in the Presence of the FDA |
|
| An Empirical Examination of Information Barriers to Trade in Insurance |
|
| Endogenous cost-effectiveness analysis in health care technology adoption |
|
| External Treatment Effects and Program Implementation Bias |
|
| The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims |
|
| Health and wealth disparities in the United States |
|
| Health Care Adherence and Personalized Medicine |
|
| How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations |
|
| The impact of comparative effectiveness research on health and health care spending |
|
| The impact of public testing for human immunodeficiency virus |
|
| Integrated Insurance Design in the Presence of Multiple Medical Technologies |
|
| International Health Economics |
|
| Is the food and drug administration safe and effective? |
|
| Is the obesity epidemic a public health problem? a decade of research on the economics of obesity |
|
| The Long-Run Growth in Obesity as a Function of Technological Change |
|
| Merit Motives and Government Intervention: Public Finance in Reverse |
|
| Mortality Contingent Claims, Health Care, and Social Insurance |
|
| Nonprofit Production and Competition |
|
| Observational Agency and Supply-Side Econometrics |
|
| Pricing and R&D with related margins |
|
| Private choices and public health : the AIDS epidemic in an economic perspective |
|
| Public Liabilities and Health Care Policy |
|
| The quantity and quality of life and the evolution of world inequality |
|
| The Rise in Old Age Longevity and the Market for Long-Term Care |
|
| Sharing R&D Risk in Healthcare via FDA Hedges |
|
| Surplus Appropriation from R&D and Health Care Technology Assessment Procedures |
|
| The Value of Life in General Equilibrium |
|
| The value of life near its end and terminal care |
|
| Who benefits from new medical technologies? : estimates of consumer and producer surpluses for HIV/AIDS drugs |
|
